Selective α7 Nicotinic Acetylcholine Receptor Ligands
Authors: Mazurov, Anatoly; Hauser, Terry; Miller, Craig H.
Source: Current Medicinal Chemistry, Volume 13, Number 13, June 2006 , pp. 1567-1584(18)
Publisher: Bentham Science Publishers
Abstract:
Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand gated ion channels of broad distribution and structural heterogeneity. Their functional diversity demonstrated involvement in a variety of neuronal processes (e.g., sensory gating and cognitive function) and generated great interest in them as targets for therapeutic intervention in a number of neuropathological conditions and diseases. In order to control distinct nicotinic functions pharmacologically, it is important to design ligands that selectively interact with distinct receptor subtypes in such a way as to maximize the therapeutic effect and minimize the adverse effects. The α7 nAChR, a CNS subtype, has been the most intensively studied nAChR in recent years. Selective α7 nAChR agonists have been developed as potential candidates for the treatment of schizophrenia, cognitive disorders (including Alzheimer's disease), and inflammation. Despite early concerns that the rapid desensitization property of the α7 nAChR would limit their therapeutic potential, several have already been advanced to clinical trials (e.g., PH-399733, Pfizer; MEM 3454, Memory Pharmaceuticals/Roche). Further development of allosteric modulators and pharmaceutically relevant antagonists might expand the therapeutic potential of compounds that target α7 nAChRs. In this review we briefly describe the structure and function of the α7 nAChR and its in vitro and in vivo pharmacology, discuss the clinical relevance of these efforts, and review the current progress in α7 ligand development.Keywords: α7 neuronal nicotinic acetylcholine receptors (nAChRs); α7 selective nicotinic ligand; quinuclidine; allosteric modulator; radiolabeled imaging ligand
Document Type: Research article
DOI: http://dx.doi.org/10.2174/092986706777442011
Affiliations: 1: Targacept, Inc., Winston- Salem, North Carolina 27101, USA.
Publication date: 2006-06-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
- In this: publication
- By this: publisher
- In this Subject: Pharmacology
- By this author: Mazurov, Anatoly ; Hauser, Terry ; Miller, Craig H.

Shopping cart
Receive new issue alert
Get Permissions